Initiates Pursuit of Scientific Advice for Iomab-B from the European Medicines Agency
Company is seeking guidance on development plan of Iomab-B for the EU market
Actinium's small and medium-sized (SME) status and orphan designation results in a 100% reduction in fees for scientific advice
NEW YORK - October 25, 2016 (Investorideas.com Newswire) Actinium Pharmaceuticals, Inc. (NYSE: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company has initiated the European Medicines Agency (EMA) Scientific Advice process for Iomab-B. The EMA provides scientific advice to companies regarding the appropriate studies for the development of a medicine. The goal of scientific advice is to facilitate the development and availability of high-quality, effective and acceptably safe medicines, for the benefits of patients.
- Published: 26 October 2016
- Written by Investor Ideas